Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

PARVOVIRUS-BASED ANTICANCER THERAPIES

Group leader: Christiane Dinsart, PhD

Contact:

Christiane Dinsart, PhD

Tel. +49 6221 42 49 65
FAX +49 6221 42 49 62
Contact form

Previous and Current Research

Some cancers have a desolate prognosis and constitute obvious targets for innovative therapies including virus-based treatments. Candidate oncolytic viruses notably include autonomous parvoviruses of rodent origin (PV). The anticancer potential of these viruses is supported by a set of observations in preclinical models. Yet the mere fact that several PVs were isolated from growing tumours, and the varying sensitivity of transformed human cell cultures to PV infection, indicate that the natural viruses are not always potent enough to override cancer cell proliferation. Nevertheless, the oncotropic nature of PVs together with their low pathogenicity, make them attractive vectors for tumour-directed therapy. Over the last few years, we have designed recombinant vectors (recPV) armed with therapeutic transgenes to reinforce their anti-neoplastic activity and/or to circumvent the resistance of tumour cells to conventional treatments. Hence, recombinant vectors based on H-1PV and MVMp have been designed to deliver immunostimulatory molecules. These immunomodulators, such as cytokines will be secreted from infected cells and induce antitumour effects by activating the immune system.

Future Projects and Goals

Since many tumours, in particular brain tumours, are highly vascularised. anti-angiogenic therapies using appropriate recPVs are worth considering. Hence revPVs will also be engineered to deliver anti-angiogenic molecules. They should combine their intrinsic oncolytic activity with the expression of different anti-angiogenic molecules in the vicinity of tumours. The ability to inhibit the tumour growth will be tested using relevant pre-clinical (human) tumour models.
Our goal is thus to provide proof of concept regarding the therapeutic potency of combinatorial treatments consisting of PVs and immunostimulatory and/or anti-angiogenic molecules
 

to top
powered by webEdition CMS